Drug Trial Radar · NCT06760819
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
111
Planned (sponsor's estimate)
Start
Feb 13, 2025
Primary completion
Feb 2, 2029
Study completion Oct 26, 2029
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Jan 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works. In this trial, the researchers want to learn how well BAY2927088 (sevabertinib) works in people with different types of solid tumors with HER2 mutations. These include tumors in the colon or rectum, the uterus and the cervix (lower part of the uterus), the breast, the bladder, and the biliary tract (includes gall bladder and bile ducts) as well as other types of solid tumors with the exception of people with advanced non-small cell lung cancer (NSCLC). Solid tumors may have specific changes or mutations to a gene called human epidermal growth receptor-2 (HER2). This leads to the formation of an abnormal form of HER2 protein in the cancer cells, resulting in increased cell growth. The study treatment, BAY2927088, is expected to block the abnormal HER2 protein which may stop the spread of cancer. The trial will include about 111 participants who are at least 18 years old. All the participants will take 20 mg of BAY2927088 as tablets by mouth. The participants will take treatments in 3-week periods called cycles. These 3-week cycles will be repeated throughout the trial. The participants can take BAY2927088 until their cancer gets worse, until they have medical problems, or until they leave the trial. During the trial, the doctors will take imaging scans of different parts of the body to study the spread of cancer and will check heart health using echocardiogram or cardiac magnetic resonance imaging (MRI) and electrocardiogram (ECG). The doctors will also take blood and urine samples and do physical examinations to check the participants' health. They will ask questions about how the participants are feeling and if they have any medical problems.
Conditions
- Advanced Solid Tumors
- HER2 Mutation
Interventions
BAY2927088Drug
tablet, oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) per RECIST 1.1 as assessed by BICRTime frame: From start of study intervention until the first documented progression, or death from any cause, or end of study (up to approximately 3 years), whichever comes first
Locations
54 sites in 11 countries. Site status is shown where the registry gives one.
UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital
Birmingham, Alabama · Not yet recruiting
City of Hope - Duarte Cancer Center
Duarte, California · Recruiting
Florida Cancer Specialists & Research Institute - Fort Myers Cancer Center - Gladiolus
Fort Myers, Florida · Recruiting
Dana-Farber Cancer Institute - Oncology Department
Boston, Massachusetts · Recruiting
Brigette Harris Cancer Pavilion at Henry Ford Cancer Center - Detroit
Detroit, Michigan · Withdrawn
Profound Research -OMG - TriAtria Cancer Center
Farmington Hills, Michigan · Withdrawn
Cleveland Clinic - Oncology Department
Cleveland, Ohio · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
The University of Texas MD Anderson Cancer Center - Texas Medical Center
Houston, Texas · Recruiting
Gynecology Oncology clinic at UW Medical Center - Montlake
Seattle, Washington · Withdrawn
UW Health Carbone Cancer Center
Madison, Wisconsin · Not yet recruiting
NSW Health - Blacktown Hospital
Blacktown, New South Wales, Australia · Recruiting
Macquarie University Hospital - Oncology Department
Sydney, New South Wales, Australia · Recruiting
ICON Cancer Centre - Southport
Southport, Queensland, Australia · Not yet recruiting
Queen Elizabeth II Health Sciences Centre | Oncology
Halifax, Nova Scotia, Canada · Withdrawn
Princess Margaret Cancer Centre | Medical Oncology and Hematology
Toronto, Ontario, Canada · Recruiting
Research Institute of the McGill University Health Centre | Women Health's Research Unit
Montreal, Quebec, Canada · Withdrawn
Peking University First Hospital - Oncology Department
Beijing, Beijing Municipality, China · Recruiting
Beijing Cancer Hospital - Oncology Department
Beijing, Beijing Municipality, China · Recruiting
Hunan Cancer Hospital - Oncology Department
Changsha, Hunan, China · Not yet recruiting
Fudan University Shanghai Cancer Center - Oncology Department
Shanghai, Shanghai Municipality, China · Recruiting
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Sir Run Run Shaw Hospital, Zhejiang Univ. School of Medicine - Oncology Department
Hangzhou, Zhejiang, China · Not yet recruiting
Rigshospitalet Copenhagen University Hospital | Oncology Department
Copenhagen, Capital Region / Region Hovedstaden, Denmark · Recruiting
Aarhus University Hospital | Oncology Department - Clinical Research Unit
Aarhus N, Central Denmark Region / Region Midtjylland, Denmark · Withdrawn
Odense University Hospital | Svendborg Sygehus - Oncology Department
Odense, Region of Southern Denmark / Region Syddanmark, Denmark · Recruiting
Centre Hospitalier Lyon Sud - Service oncologie medicale
Pierre-Bénite, Auvergne-Rhône-Alpes, France · Recruiting
CHU Brest - Hopital La Cavale Blanche - service oncologie medicale
Brest, Brittany Region, France · Recruiting
Centre Oscar Lambret - Service Oncologie
Lille, Hauts-de-France, France · Not yet recruiting
Institut Gustave Roussy - Departement d'Innovation Therapeutique et d'Essais Precoces (DITEP)
Villejuif, Île-de-France Region, France · Recruiting
Institut Bergonie - Unicancer Nouvelle Aquitaine - Service Oncologie medicale
Bordeaux, New Aquitaine, France · Recruiting
ICM - Institut du Cancer de Montpellier - Val d'Aurelle - CIPP
Montpellier, Occitanie, France · Not yet recruiting
Azienda USL IRCCS di Reggio Emilia_Arcispedale Santa Maria Nuova - S.C. Oncologia Provinciale
Reggio Emilia, Emilia-Romagna, Italy · Not yet recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Oncologia Medica
Rome, Lazio, Italy · Recruiting
Fondazione IRCCS Istituto Nazionale dei Tumori - S. C. Oncologia Medica 1
Milan, Lombardy, Italy · Recruiting
Istituto Europeo di Oncologia s.r.l - Ginecologia Oncologica Medica
Milan, Lombardy, Italy · Not yet recruiting
Aichi Cancer Center Hospital
Nagoya, Aichi-ken, Japan · Recruiting
National Cancer Center Hospital East (NCCHE) - Kashiwa Campus
Kashiwa, Chiba, Japan · Recruiting
Hokkaido University Hospital
Sapporo, Hokkaido, Japan · Recruiting
Kindai University Hospital
Sakai, Osaka, Japan · Recruiting
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.